Skip to main content

Table 3 Clinical Study Duration

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

 

Eptinezumab 100 mg

Eptinezumab 300 mg

Eptinezumab 1000 mg

Placebo

N = 701

N = 695

N = 81

N = 791

Total Time in Clinical Study, n (%)

  ≥12 weeks

680 (97.0)

681 (98.0)

78 (96.3)

766 (96.8)

  ≥24 weeks

642 (91.6)

649 (93.4)

46 (56.8)

692 (87.5)

  ≥36 weeks

288 (41.1)

293 (42.2)

N/A

280 (35.4)

  ≥48 weeks

263 (37.5)

270 (38.8)

N/A

256 (32.4)

  1. Total Exposure Time = Last day on study – first dose date + 1. N/A Not applicable